Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- One Year Needed to Complete Merger with Schering: Mr Eiki of Bayer
November 6, 2006
- REGULATORY NEWS IN BRIEF
November 6, 2006
- Eisai Completes Acquisition of 4 Oncology-Related Products from Ligand
November 6, 2006
- Proteins Predict Necessity of Lung Cancer Adjuvant Therapy
November 6, 2006
- BUSINESS NEWS IN BRIEF
November 6, 2006
- Sixteen Genes that Predict Therapeutic Results Discovered
November 6, 2006
- There Will Be No NHI Price Revision Next April
November 6, 2006
- 8th Annual Meeting of the Japan Osteoporosis Society
November 6, 2006
- Price Agreement Rate Was 46.8% with Med. Institutions as of July
November 6, 2006
- Recommendation Grades of Drugs to Treat Osteoporosis Included in 2006 GL
November 6, 2006
- 24 New Drugs Approved
November 6, 2006
- R&DNEWS IN BRIEF
November 6, 2006
- SEMINAR
November 6, 2006
- Korosho to Question Major Pharmacy Chains on What They Do to Promote Use of Generics
October 30, 2006
- MIC Medical Expands Medical Image Analysis Business
October 30, 2006
- HIB Urges Pharmacies to Help Promote Use of GE Drugs
October 30, 2006
- AdvaMed
October 30, 2006
- Taiyo Yakuhin Aims to Be "Most Trusted Generic Drug Company"
October 30, 2006
- MEDICAL DEVICE NEWS IN BRIEF
October 30, 2006
- 2006 Symposium of APEC Network on Pharma Regulatory Science
October 30, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…